Across 186 Phase II cell therapy trials authorized in 2024–2026, EU activity is highly concentrated in academic hospital systems with hematology, oncology, immunology, transplant, and advanced therapy infrastructure. The strongest recurring site signals are AP-HP in France, Charité in Germany, and Clínica Universidad de Navarra in Spain, while 2024 accounts for nearly two thirds of the analyzed trial cohort.
The dataset includes 117 / 186 trials in 2024 (62.9%), 56 / 186 in 2025 (30.1%), and 13 / 186 in 2026 (7.0%).
The cohort is dominated by 2024-authorized studies, meaning the site ranking mainly reflects centers that were already active in the early CTIS cell therapy wave rather than only the newest 2026 submissions.
Among the top 10 recurring site systems, AP-HP accounts for 45 site records, Charité for 20, and Clínica Universidad de Navarra for 18. These three systems together represent 83 / 123 ranked top-site records (67.5%).
| Rank | Site system | Country | Records |
|---|---|---|---|
| 1 | Assistance Publique–Hôpitaux de Paris / AP-HP | France | 45 |
| 2 | Charité Universitätsmedizin Berlin | Germany | 20 |
| 3 | Clínica Universidad de Navarra | Spain | 18 |
| 4 | Universitair Medisch Centrum Utrecht | Netherlands | 9 |
| 5 | Hospital Clinic de Barcelona | Spain | 5 |
| 6 | Institut Gustave Roussy | France | 4 |
| 7 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Italy | 4 |
| 8 | Hospital Universitario La Paz | Spain | 4 |
| 9 | Hospital Sant Joan de Déu Barcelona | Spain | 3 |
| 10 | Hospices Civils de Lyon | France | 3 |
The leading sites are not isolated hospitals but multi-department academic systems. This pattern is consistent with Phase II cell therapy trials needing hematology/oncology units, transplant services, immunology expertise, apheresis or cell-processing adjacency, and intensive monitoring capacity.
The cohort spans oncology, hematology-oncology, immunology, nephrology, rare disease, ophthalmology, musculoskeletal, transplant, and inflammatory conditions. In the top recurring site group, oncology/hematology-focused records account for 69 / 123 records (56.1%), while immunology/transplant/other disease areas account for 54 / 123 (43.9%).
Cell therapy Phase II development is broader than oncology alone. The same elite academic systems often support oncology, autoimmune, transplant, and rare-disease programs, making cross-specialty operational capacity an important differentiator.
The strongest country-level signals align with the top site systems: France, Germany, Spain, the Netherlands, and Italy dominate recurring site visibility. Together, these five countries account for 112 / 123 ranked top-site records (91.1%).